omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

CEO

Gregory Demopulos

omeros.com →

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

News

Franklin BSP Realty Trust: Welcoming The Preferred Shares To The 9% Club

CEF Market Weekly Review: CLOpocalypse Continues

2 Defensive Healthcare Stocks to Buy Right Now

Top Stocks to Double Up on Right Now

Live Oak Bancshares CEO Sells 20000 Shares for $653000

Bold Prediction: SMH Is About to Soar. Here's Why.

1 Tesla Competitor That Could Unseat the EV Giant by 2029

Where Will Palantir Stock Be in 3 Years?

Is the Vanguard S&P 500 ETF the Smartest Investment You Can Make Before March Ends?

Prediction: While Big Tech Grabs Headlines, These Small AI Stocks Could Outperform

Qualcomm: The Market Is Missing The Optionality

Carvana: Gross Profit Per Unit Headwinds Are Temporary

WYBOT stellt den S3 vor und setzt neue Maßstäbe bei der automatischen Poolreinigung

Power Solutions: Market Overreacting To Temporary Margin Pressure, Reiterating Strong Buy

Global Partners LP COO Sells Nearly $740000 Worth of Units

The Social Security Fairness Act Paid Out $17 Billion in Retroactive Benefits. Here's Who Qualifies.

The Dip Before The Re-Rate, Xiaomi's Window Of Maximum Pessimism

SCHD: Your Complete Guide To The March 2026 Index Reconstitution

Crypto News: Pepeto Goes Viral While XRP Price Prediction Might Reach $10 Soon

Crypto News: Pepeto Eliminates Ethereum Fees While XRP Price Prediction Targets $8 and Whale Wallets Are Moving

About